Calamos Advisors’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Calamos Advisors’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-375,000	Closed	-$3.7M	–	1459
2022 Q2	$3.7M	Hold	375,000	–	–	0.02%	798
2022 Q1	$3.66M	Hold	375,000	–	–	0.01%	797
2021 Q4	$3.71M	Hold	375,000	–	–	0.01%	786
2021 Q3	$3.75M	Hold	375,000	–	–	0.02%	682
2021 Q2	$3.79M	Buy	+375,000	New	+$3.78M	0.02%	626

Other funds holding ORIAU

JNE Partners London, United Kingdom $243M AUM 2.37% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Calamos Advisors's ORIAU Position: Q3 2022 in Review

Calamos Advisors sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q3 2022, closing a stake of 375,000 shares — an estimated $3.7M sold.

Calamos Advisors first reported a position in ORIAU in Q2 2021 and held it in 5 quarters. The position peaked at $3.79M in Q2 2021. 11 funds tracked by Wall St. Rank hold ORIAU as of Q3 2022.

Calamos Advisors reported no remaining Orion Biotech Opportunities Corp. Units position as of Q3 2022 after selling out during the quarter.
Calamos Advisors sold 375,000 Orion Biotech Opportunities Corp. Units shares in Q3 2022, an estimated $3.7M.
Calamos Advisors first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 5 quarters.
Calamos Advisors's Orion Biotech Opportunities Corp. Units position peaked at $3.79M in Q2 2021.
11 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.